| Hazard Information | Back Directory | [Uses]
Dapiglutide is a novel dual GLP-1 and GLP-2 receptor agonist, primarily indicated for the treatment of short bowel syndrome-associated intestinal dysfunction[1]. | [References]
[1] Reiner, J., Berlin, P., Held, J., Thiery, J., Skarbaliene, J., Griffin, J., Russell, W., Eriksson, P.-O., Berner-Hansen, M., Ehlers, L., Vollmar, B., Jaster, R., Witte, M., Lamprecht, G. (2022). Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel. Journal of Parenteral and Enteral Nutrition, 46 5, 1107–1118. https://doi.org/10.1002/jpen.2286 |
|
| Company Name: |
YantaiBio
|
| Telephone: |
13758194781; 13758194781 |
| Website: |
|
|